Case 2: A 48-Year-Old Man with Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.
Watch
AGAVE-201 Data on Refractory cGvHD
May 7th 2024In this expert analysis of the AGAVE-201 trial data, the efficacy of a monoclonal antibody in treating graft versus host disease is discussed, with the lowest dose of 0.3 mg/kg administered every 2 weeks demonstrating the highest response rates, exceeding 75%.
Watch
Treatment Approaches for Myeloproliferative Neoplasms
May 6th 2024This segment discusses the current classification of myeloproliferative neoplasms (MPNs) and the pathogenesis of these disorders, particularly the role of the JAK-STAT signaling pathway. It also presents a treatment algorithm for higher-risk myelofibrosis, with a focus on the use of JAK inhibitors such as ruxolitinib, fedratinib, pacritinib, and momelotinib.
Watch
Key Findings From BOND-003: Cretostimogene Grenadenorepvec in NMIBC
May 3rd 2024Mark D. Tyson, II, MD, MPH, discusses the safety and efficacy findings from the BOND-003 trial of cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Watch
LITESPARK-005: Belzutifan in Previously Treated Advanced Clear Cell RCC
Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.
Watch
Clinical Trials Evaluating Lenvatinib Plus Everolimus in Advanced Renal Cell Carcinoma
The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.
Watch
Background, Methods, and Design of BOND-003 in NMIBC
May 3rd 2024Mark D. Tyson, II, MD, MPH, discusses the background of the phase 3 BOND-003 study evaluating cretostimogene grenadenorepvec in patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Watch
Emerging Therapies for Refractory cGvHD: Potential Advantages of Axatilimab
May 3rd 2024The final segment explores the potential role of axatilimab, a novel agent, in the management of refractory cGvHD, highlighting its mechanism of action and potential efficacy compared to existing treatment options.
Watch
Quality of Life + Clinical Monitoring Outside the Transplant Center
April 30th 2024Yi-Bin Chen, MD, proposes a strategy to enhance patients' quality of life by utilizing virtual monitoring as an alternative to requiring patients to travel to a transplant center, which includes regular remote assessments of blood work, such as liver function tests, lipid panels, and immunoglobulin levels.
Watch